Search

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
GET IN TOUCH
Our Company Recognitions

Recognitions

Awards

View all Awards
Great Place To Work®

Aragen receives Great Place to Work certification for the 6th consecutive year

February 2025
Platinum rating from EcoVadis

Aragen receives Platinum rating from EcoVadis for its sustainability initiatives

December 2024
SBTi Approval for near-term and net-zero targets

First CRDMO to receive approval for near-term and net-zero targets from the Science Based Targets initiative (SBTi) in India

September 2024
View all Awards

Testimonials

View all Testimonials
Dr. Kathleen Shelton Vice President and Chief Technology Officer
FMC Corporation
“Aragen has been a valued collaborator of FMC for several years. This partnership extends across multiple disciplines in research and development and we appreciate our strong working relationship.”
Rajat Sood Managing Director
Goldman Sachs Asset Management
“Aragen is well positioned to benefit from the secular trend of increased outsourcing by the life sciences industry. With a clear value creation plan in place, we look forward to closely working with the management and shareholders of Aragen. Goldman Sachs is actively seeking to invest and foster leading, national champions of India who are building companies of a global scale.”
Alan Joslyn, Ph.D. President and CEO
Oragenics Inc.
“Developing a variety of vaccine alternatives is critical to bringing the SARS-Cov-2 pandemic under control. Utilizing the technology created at NIH with Aragen’s pre-clinical development capabilities will help us accelerate the development of the TerraCov2 vaccine candidate. We believe the relationship between the companies will result in advancement of the vaccine candidate into the clinic as rapidly as possible,”
View all Testimonials

Publications

View all Publications
2019

Chemistry

Galeterone and the Next Generation Galeterone Analogs, VNPP414 and VNPP433-3β Exert Potent Therapeutic Effects in Castration-/Drug-resistant Prostate Cancer Preclinical Models in vitro and in vivo

Andrew K. Kwegyir-Afful, Senthilmurugan Ramalingam, Vidya P. Ramamurthy, Puranik Purushottamachar, Francis N. Murigi, Tadas S. Vasaitis, Weiliang Huang, Maureen A. Kane, Yuji Zhang, Nicholas Ambulos, Sudhir Tiwari, Pratima Srivastava, Ivo P. Nnane, Arif Hussain, Yun Qiu, David J. Weber, Vincent C. O. Njar
(Basel). 2019 Nov; 11(11), 1637

Chemistry

Chemistry

Oxidative Degradation Profile Studies of Tavaborole by a Validated Stability Indicating RP-UPLC method: Isolation and Characterization of Novel Degradant using 2D-NMR and HRMS

Umamaheshwar Puppala , Vishnu Murthy Marisetti, Koduri S V Srinivas, K Venkateshwara Reddy, Muralidharan Kaliyaperumal, Raju Doddipalla
Biomedical Chromatography | Language: English, Database: CAplus and MEDLINE

Chemistry

Biology

Mass Spectrometry as a Workhorse for Preclinical Drug Discovery: Special Emphasis on Drug Metabolism and Pharmacokinetics

Vijayabhaskar Veeravalli, Lakshmi Mohan Vamsi Madgula, Pratima Srivastava
10.5772/intechopen.88385. In book: Mass Spectrometry – Future Perceptions and Applications

Download

Biology

View all Publications

Related Links

Working at Aragen

Find out what keeps us motivated, everyday.

Read more
Media & Events

Access the latest and archived media stories, events and our press kit.

Read more
About Us

We are a trusted R&D and manufacturing partner to the global life sciences industry.

Read more